The efficacy and safety of incobotulinumtoxinA ≤400 U was demonstrated in subjects with post-stroke upper-limb spasticity in a randomized, double-blind Phase 3 study with an open-label extension (OLEX; EudraCT number 2005-003951-11, NCT00432666). We report a post-hoc analysis of the duration of the treatment effect. Subjects completing the placebo-controlled main period (single injection cycle with 12-20-week observation) entered the OLEX and received a maximum of five further treatments (maximum duration 69 weeks) with incobotulinumtoxinA ≤400 U at flexible intervals with a minimum duration of 12 weeks, based on clinical need. Intervals between two consecutive incobotulinumtoxinA injections, excluding treatment intervals prior to the end-of-study visit, were evaluated. Of 437 incobotulinumtoxinA treatment intervals, 415 received by 136 subjects were included in the post-hoc analysis. More than half (52.3%; 217/415) of all incobotulinumtoxinA reinjections were administered at Week ≥14, 31.1% (129/415) at Week ≥16, 19.0% (79/415) at Week ≥18, and 11.6% (48/415) at Week ≥20. The duration of effect may vary and can exceed 20 weeks or more, which was observed in at least one injection cycle in 29.4% (40/136) subjects over the course of their treatment. Data show that incobotulinumtoxinA retreatment for upper-limb spasticity may not be required at 12-week intervals and provides evidence for flexible treatment intervals beyond this time frame.

Department of Physical Medicine and Rehabilitation and the Department of Neurology Northwestern University Feinberg School of Medicine and Shirley Ryan AbilityLab Chicago IL United States

Faculty of Medicine and Dentistry and University Hospital Palacký University Olomouc Olomouc Czechia

Merz Pharmaceuticals GmbH Frankfurt am Main Germany

Moss Rehabilitation Philadelphia PA United States

See more in PubMed

Urban PP, Wolf T, Uebele M, Marx JJ, Vogt T, Stoeter P, et al. . Occurrence and clinical predictors of spasticity after ischemic stroke. Stroke. (2010) 41:2016–20. 10.1161/STROKEAHA.110.581991 PubMed DOI

Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology. (2013) 80:S13–9. 10.1212/WNL.0b013e3182762448 PubMed DOI

Doan QV, Brashear A, Gillard PJ, Varon SF, Vandenburgh AM, Turkel CC, et al. . Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity. PM&R. (2012) 4:4–10. 10.1016/j.pmrj.2011.10.001 PubMed DOI

Sturm JW, Donnan GA, Dewey HM, Macdonell RA, Gilligan AK, Srikanth V, et al. Quality of life after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. (2004) 35:2340–5. 10.1161/01.STR.0000141977.18520.3b PubMed DOI

Marciniak C, Munin MC, Brashear A, Rubin BS, Patel AT, Slawek J, et al. . IncobotulinumtoxinA treatment in upper-limb poststroke spasticity in the open-label extension period of PURE: efficacy in passive function, caregiver burden, and quality of life. PM&R. (2020) 12:491–9. 10.1002/pmrj.12265 PubMed DOI

Gillard PJ, Sucharew H, Kleindorfer D, Belagaje S, Varon S, Alwell K, et al. . The negative impact of spasticity on the health-related quality of life of stroke survivors: a longitudinal cohort study. Health Qual. Life Outcomes. (2015) 13:159. 10.1186/s12955-015-0340-3 PubMed DOI PMC

Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists in Neurology, Royal College of Occupational Therapists Spasticity in Adults: Management Using Botulinum Toxin. National Guidelines. (2018). Available online at: https://www.rcplondon.ac.uk/sites/default/files/documents/spasticity-in-adults-management-botulinum-toxin.pdf (accessed October 2, 2019).

Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM, et al. . European consensus table on the use of botulinum toxin type A in adult spasticity. J. Rehabil. Med. (2009) 41:13–25. 10.2340/16501977-0303 PubMed DOI

Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. . Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. (2016) 86:1818–26. 10.1212/WNL.0000000000002560 PubMed DOI PMC

Esquenazi A, Novak I, Sheean G, Singer BJ, Ward AB. International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments-introduction. Eur. J. Neurol. (2010) 17:1–8. 10.1111/j.1468-1331.2010.03125.x PubMed DOI

Merz Pharma UK Ltd Xeomin® (50/100/200) Summary of Product Characteristics. (2020). Available online at: https://www.medicines.org.uk/emc/product/2162/smpc (accessed March 19, 2020).

Merz Pharmaceuticals LLC Highlights of Prescribing Information – Xeomin®. (2019). Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125360s074lbl.pdf (accessed October 7, 2020).

Elovic EP, Munin MC, Kaňovský P, Hanschmann A, Hiersemenzel R, Marciniak C. Randomized, placebo-controlled trial of incobotulinumtoxinA for upper-limb post-stroke spasticity. Muscle Nerve. (2016) 53:415–21. 10.1002/mus.24776 PubMed DOI PMC

Marciniak C, Munin MC, Brashear A, Rubin BS, Patel AT, Slawek J, et al. . IncobotulinumtoxinA efficacy and safety in adults with upper-limb spasticity following stroke: results from the open-label extension period of a phase 3 study. Adv. Ther. (2019) 36:187–99. 10.1007/s12325-018-0833-7 PubMed DOI PMC

Kaňovský P, Slawek J, Denes Z, Platz T, Sassin I, Comes G, et al. . Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin. Neuropharmacol. (2009) 32:259–65. 10.1097/WNF.0b013e3181b13308 PubMed DOI

Kaňovský P, Slawek J, Denes Z, Platz T, Comes G, Grafe S, et al. . Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J. Rehabil. Med. (2011) 43:486–92. 10.2340/16501977-0796 PubMed DOI

Barnes M, Schnitzler A, Medeiros L, Aguilar M, Lehnert-Batar A, Minnasch P. Efficacy and safety of NT 201 for upper limb spasticity of various etiologies – a randomized parallel-group study. Acta Neurol. Scand. (2010) 122:295–302. 10.1111/j.1600-0404.2010.01354.x PubMed DOI

Wissel J, Bensmail D, Ferreira JJ, Molteni F, Satkunam L, Moraleda S, et al. . Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: the TOWER study. Neurology. (2017) 88:1321–8. 10.1212/WNL.0000000000003789 PubMed DOI PMC

Bensmail D, Hanschmann A, Wissel J. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians). J. Med. Econ. (2014) 17:618–25. 10.3111/13696998.2014.925462 PubMed DOI

Evidente VGH, Fernandez HH, LeDoux MS, Brashear A, Grafe S, Hanschmann A, et al. . A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystonia. J. Neural. Transm. (2013) 120:1699–707. 10.1007/s00702-013-1048-3 PubMed DOI PMC

Truong DD, Gollomp SM, Jankovic J, LeWitt PA, Marx M, Hanschmann A, et al. . Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm. J. Neural. Transm. (2013) 120:1345–53. 10.1007/s00702-013-0998-9 PubMed DOI PMC

Esquenazi A, Delgado MR, Hauser RA, Picaut P, Foster K, Lysandropoulos A, et al. . Duration of symptom relief between injections for abobotulinumtoxina (Dysport®) in spastic paresis and cervical dystonia: comparison of evidence from clinical studies. Front. Neurol. (2020) 11:576117. 10.3389/fneur.2020.576117 PubMed DOI PMC

Gracies JM, O'Dell M, Vecchio M, Hedera P, Kocer S, Rudzinska-Bar M, et al. . Effects of repeated abobotulinumtoxinA injections in upper limb spasticity. Muscle Nerve. (2018) 57:245–54. 10.1002/mus.25721 PubMed DOI PMC

Poliziani M, Koch M, Liu X. Striving for more good days: patient perspectives on botulinum toxin for the treatment of cervical dystonia. Patient Prefer Adherence. (2016) 10:1601–8. 10.2147/PPA.S106560 PubMed DOI PMC

Sethi KD, Rodriguez R, Olayinka B. Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J. Med. Econ. (2012) 15:419–23. 10.3111/13696998.2011.653726 PubMed DOI

Chandra S, Afsharipour B, Rymer WZ, Suresh NL. Precise quantification of the time course of voluntary activation capacity following botulinum toxin injections in the biceps brachii muscles of chronic stroke survivors. J. Neuroeng. Rehabil. (2020) 17:102. 10.1186/s12984-020-00716-z PubMed DOI PMC